{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:45:11Z","timestamp":1795023911280,"version":"4.10.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14617-8","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T15:22:12Z","timestamp":1753197732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Kuan-Yu","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiann-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-520X","authenticated-orcid":false,"given":"Hsin-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"14617_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72(1):7\u201333.","DOI":"10.3322\/caac.21708"},{"issue":"3","key":"14617_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"4","key":"14617_CR3","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"14617_CR4","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/bjs.11295","volume":"106","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106(12):1590\u2013601.","journal-title":"Br J Surg"},{"issue":"12","key":"14617_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"14","key":"14617_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381.","journal-title":"JAMA"},{"issue":"2","key":"14617_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147\u201356.","journal-title":"JAMA"},{"issue":"10073","key":"14617_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London England). 2017;389(10073):1011\u201324.","journal-title":"Lancet (London England)"},{"issue":"25","key":"14617_CR9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"issue":"13","key":"14617_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and taiwan: GEST study. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31(13):1640\u20138.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10041","key":"14617_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet (London England). 2016;388(10041):248\u201357.","journal-title":"Lancet (London England)"},{"issue":"2","key":"14617_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jso.23068","volume":"106","author":"Y Murakami","year":"2012","unstructured":"Murakami Y, Uemu ra K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. J Surg Oncol. 2012;106(2):174\u201380.","journal-title":"J Surg Oncol"},{"key":"14617_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34580","author":"Y Tomimaru","year":"2022","unstructured":"Tomimaru Y, Eguchi H, Inoue Y, Nagakawa Y, Ohba A, Takami H, et al. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan pancreas society based on real-world data. Cancer. 2022. https:\/\/doi.org\/10.1002\/cncr.34580.","journal-title":"Cancer"},{"key":"14617_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2022.06.043","volume":"173","author":"LY Bai","year":"2022","unstructured":"Bai LY, Li CP, Shan YS, Chuang SC, Chen JS, Chiang NJ, et al. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study. European journal of cancer (Oxford, England: 1990). 2022;173:123\u201332.","journal-title":"European journal of cancer (Oxford, England: 1990).."},{"issue":"6","key":"14617_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.amjsurg.2007.04.018","volume":"195","author":"Y Murakami","year":"2008","unstructured":"Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakagawa N, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg. 2008;195(6):757\u201362.","journal-title":"Am J Surg"},{"issue":"8","key":"14617_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/jhbp.1151","volume":"29","author":"N Kondo","year":"2022","unstructured":"Kondo N, Uemura K, Sumiyoshi T, Okada K, Seo S, Otsuka H, et al. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: analysis using inverse probability of treatment weighting. Journal of Hepato-Biliary-Pancreatic Sciences. 2022;29(8):911\u201321.","journal-title":"Journal of Hepato-Biliary-Pancreatic Sciences"},{"key":"14617_CR17","first-page":"100841","volume-title":"Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: retrospective real-world data","author":"H Tang","year":"2022","unstructured":"Tang H, Qiao C, Lu J, Cheng Y, Dai M, Zhang T, et al. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: retrospective real-world data. Volume 34. New York, NY: Neoplasia; 2022. p. 100841."},{"issue":"15suppl","key":"14617_CR18","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1200\/JCO.2019.37.15_suppl.4126","volume":"37","author":"S Satoi","year":"2019","unstructured":"Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, et al. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II\/III trial; Prep-02\/JSAP-05). J Clin Oncol. 2019;37(15suppl):4126.","journal-title":"J Clin Oncol"},{"issue":"4","key":"14617_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jhbp.1245","volume":"30","author":"Y Yabushita","year":"2023","unstructured":"Yabushita Y, Matsuyama R, Miyake K, Homma Y, Kumamoto T, Misumi T, et al. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences. 2023;30(4):493\u2013502.","journal-title":"Journal of Hepato-Biliary-Pancreatic Sciences"},{"issue":"12","key":"14617_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2021.3603","volume":"7","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Lordick F, Fazio N. Adjuvant chemotherapy for stage I pancreatic ductal Adenocarcinoma-Is it based on evidence or clinical wisdom?? JAMA Oncol. 2021;7(12):1759\u201360.","journal-title":"JAMA Oncol"},{"issue":"7","key":"14617_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.hpb.2017.03.002","volume":"19","author":"KT Ostapoff","year":"2017","unstructured":"Ostapoff KT, Gabriel E, Attwood K, Kuvshinoff BW, Nurkin SJ, Hochwald SN. Does adjuvant therapy improve overall survival for stage IA\/B pancreatic adenocarcinoma? HPB. 2017;19(7):587\u201394.","journal-title":"HPB"},{"issue":"3","key":"14617_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3724\/zdxbyxb-2021-0194","volume":"50","author":"J Shi","year":"2021","unstructured":"Shi J, Li X, Wu Y. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study. Journal of Zhejiang University (Medical Sciences). 2021;50(3):375\u201382.","journal-title":"Journal of Zhejiang University (Medical Sciences)"},{"issue":"29","key":"14617_CR23","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","volume":"28","author":"JL Van Laethem","year":"2010","unstructured":"Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study. J Clin Oncology: Official J Am Soc Clin Oncol. 2010;28(29):4450\u20136.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"4","key":"14617_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ijrobp.2014.07.024","volume":"90","author":"AG Morganti","year":"2014","unstructured":"Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, et al. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):911\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"14617_CR25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1245\/s10434-011-2020-9","volume":"19","author":"S Hata","year":"2012","unstructured":"Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, et al. Prognostic impact of postoperative serum CA 19\u2013\u20099 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19(2):636\u201341.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"14617_CR26","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1245\/s10434-018-6521-7","volume":"25","author":"CJ Rieser","year":"2018","unstructured":"Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann Surg Oncol. 2018;25(12):3483\u201391.","journal-title":"Ann Surg Oncol"},{"key":"14617_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2021.03.036","volume":"150","author":"A Kurreck","year":"2021","unstructured":"Kurreck A, Weckwerth J, Modest DP, Striefler JK, Bahra M, Bischoff S, et al. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. European journal of cancer (Oxford, England: 1990). 2021;150:250\u20139.","journal-title":"European journal of cancer (Oxford, England: 1990)."},{"issue":"4","key":"14617_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.pan.2016.04.007","volume":"16","author":"H Imaoka","year":"2016","unstructured":"Imaoka H, Shimizu Y, Senda Y, Natsume S, Mizuno N, Hara K, et al. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study. Pancreatology. 2016;16(4):658\u201364.","journal-title":"Pancreatology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14617-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:03:45Z","timestamp":1757268225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14617-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14617"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14617-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki, and the institutional review board of Taichung Veterans General Hospital approved the study and waived the requirement for informed consent due to its retrospective design (No. CE22475A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1200"}}